Provided by Tiger Trade Technology Pte. Ltd.

Solid Biosciences

6.52
+0.29004.65%
Post-market: 6.520.00000.00%19:00 EST
Volume:1.89M
Turnover:12.27M
Market Cap:507.97M
PE:-2.63
High:6.63
Open:6.40
Low:6.35
Close:6.23
52wk High:7.37
52wk Low:2.41
Shares:77.91M
Float Shares:37.61M
Volume Ratio:1.71
T/O Rate:5.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4800
EPS(LYR):-3.0550
ROE:-86.83%
ROA:-43.67%
PB:2.33
PE(LYR):-2.13

Loading ...

Solid Biosciences CTO Paul Herzich Reports Sale of Common Shares

Reuters
·
4 hours ago

Solid Biosciences Leadership Quietly Unloads a Wave of Insider Shares

TIPRANKS
·
1 hour ago

Solid Biosciences CEO Alexander Cumbo Reports Disposal of Common Shares

Reuters
·
4 hours ago

Solid Biosciences CEO to Present at Guggenheim Emerging Outlook Biotech Summit

Reuters
·
Yesterday

Solid Biosciences participates in a conference call with Cantor

TIPRANKS
·
Feb 04

Solid Biosciences: Leveraging Next-Generation Gene Therapy in DMD to Support a Buy-Rated Risk-Reward Profile

TIPRANKS
·
Feb 03

Solid Biosciences Price Target Maintained With a $16.00/Share by Needham

Dow Jones
·
Jan 15

Solid Biosciences: Advancing DMD Gene Therapy Toward 2026 Value Inflection With Accelerated Approval Potential

TIPRANKS
·
Jan 15

Solid Biosciences Climbs After Multiple Trial Updates

Dow Jones
·
Jan 15

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101

GlobeNewswire
·
Jan 14

BRIEF-Solid Biosciences Receives FDA Orphan Drug Designation For Sgt-212 Dual-Route Gene Therapy

Reuters
·
Jan 13

FDA Grants Orphan Drug Designation to Solid Biosciences' SGT-212 for Friedreich’s Ataxia

Reuters
·
Jan 13

Solid Biosciences Receives FDA Orphan Drug Designation for Sgt-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

THOMSON REUTERS
·
Jan 13

Solid Biosciences- Dosing of First Participant in Phase 1B Falcon Trial Completed, Initial Data Expected in H2 2026

THOMSON REUTERS
·
Jan 13

Solid Biosciences doses first participant in Phase 1b FALCON trial on SGT-212

TIPRANKS
·
Jan 12

Solid Biosciences Doses First Participant in Phase 1b Trial of SGT-212 Gene Therapy for Friedreich’s Ataxia

Reuters
·
Jan 12

Solid Biosciences Inc: Expect to Share an Initial Data Update in Second Half of 2026

THOMSON REUTERS
·
Jan 12

Solid Biosciences Doses First Participant in First-in-Class Phase 1B Falcon Trial Evaluating Sgt-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

THOMSON REUTERS
·
Jan 12

Solid Biosciences Grants 7,000 RSUs to New Employee Under Inducement Plan

Reuters
·
Jan 06

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 06